D DBV Technologies SA
D
Fermé
2.374 -1.58
Résumé
Variation du prix de l'action
24h
Min
2.352
Max
2.402
Revenu | -2.8M -50M |
|---|---|
Ventes | -200K 700K |
BPA | -0.05 |
Marge bénéficiaire | -7,200 |
Employés | 170 |
EBITDA | -1.2M -47M |
Prochains Résultats | 28 oct. 2026 |
|---|
Capitalisation Boursière | -64M 768M |
|---|---|
Ouverture précédente | 3.95 |
Clôture précédente | 2.374 |
DBV Technologies SA Graphique
Les performances passées ne sont pas un indicateur fiable des résultats futurs.
Actualités Associées
Comparaison
Variation de prix
DBV Technologies SA prévision
Éléments financiers
Frais Généraux et Administratifs
Dépenses d'exploitation
Résultat avant impôt
Ventes
Coût des ventes
Marge brute des ventes
Charges d'intérêt sur la dette
EBITDA
Bénéfice d'exploitation
$
À Propos DBV Technologies SA
DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow's milk protein allergy and eosinophilic esophagitis. The company's earlier stage research programs includes vaccine for the respiratory syncytial virus, potential treatments for inflammatory bowel disease, celiac disease, and type I diabetes. In addition, it develops Viaskin technology platform, a platform to potentially treat food allergy. The company has a collaboration with Nestlé Health Science to develop MAG1C, a ready-to-use atopy patch test for the diagnosis of non-IgE mediated CMPA in infants and toddlers. DBV Technologies S.A. was incorporated in 2002 and is headquartered in Montrouge, France.